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Abstract
Critical care in the oncology population consists of diverse levels of diseases, syn‐
dromes, and emergencies that are not observed in typical medically‐ill patients and,
with it, comes even more specialized treatment strategies. Therefore, the uncommon or
less  well‐understood  pharmacologic  considerations  in  this  population  must  be
discussed to better assist any clinician at the bedside. This chapter outlines some of the
situations commonly encountered in this setting such as the challenge of treating and
preventing infectious diseases when the patient lacks the ability to mount appropriate
immune responses to conventional therapy, the paradigm of treating thromboembolism
in the group of patients who are at highest risk for both bleeding and clotting and
treatment of acute and long‐term consequences of cancer or chemotherapy requiring
escalation of care to the intensive care unit (ICU).
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1. Introduction
Common diseases and syndromes are identified in intensive care unit (ICU) oncology patients
secondary to the progression of cancer or chemotherapy. Such challenges include frequent
infections, thromboembolism with concomitant bleeding in lieu of sepsis, and toxicity from
chemotherapy, leading to emergent ICU admission. The optimal treatment strategies for these
syndromes become especially challenging in ICU patients with multi‐system organ failure and
tenuous clinical status. Furthermore, specific pharmacologic differences exist not only in ICU
but more specifically in oncology patients. Therefore, we sought to provide clinicians with
information that would help them make the appropriate and safest decisions when selecting
therapy for such critically ill patients.
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2. Antimicrobial therapy in oncology patients with sepsis
“Patients with cancer have a 30% higher risk for death from sepsis which accounts for
approximately 10% of all cancer deaths” [1]. Hematologic cancers (66.4 per 1000) have a higher
mortality rate and are more likely to develop severe sepsis compared to solid tumors (7.6 per
1000). The source of sepsis can be related to the site of the primary tumor as observed in the
frequency with which lung cancer patients acquire respiratory infections or prostate cancer
patients acquire genitourinary infections [1]. Disruption in mucosal and integumentary
systems, neutropenia, cellular and humoral immune dysfunction, splenectomy, presences of
indwelling vascular catheters, and local tumor effects are some risk factors of developing
infection in cancer patients.
It is necessary to understand the preferred regimens so therapy can be tailored to the most
likely source of infection. Furthermore, it is crucial to optimize the pharmacodynamics of
antimicrobials in critically ill oncology patients to augment outcomes. Outlined here are
several of the infectious disease‐related phenomena unique to the critically ill oncology
population including the treatment regimens. Guidelines should be referenced for the
appropriate time to de‐escalate or discontinue treatment regimens. Furthermore, primary
antibiotic choice should be based on local susceptibility patterns and formulary agents.
2.1. Neurosurgical-related bacterial meningitis
Bacterial meningitis is one of the most common CNS infections in hematopoietic stem cell
transplant and neurosurgical patients who are commonly transferred after surgery to the ICU
for continued post‐op monitoring of intracranial pressure (ICP), cerebral perfusion pressure
(CPP), and neurological status. Patients with primary and systemic metastasis from brain
tumors who had neurosurgical procedures account for 25% of cancer patients who develop
CNS infections. Risk factors include barrier disruption, poor wound healing due to radiation
therapy, and those with Ommaya reservoirs frequently used for fluid sampling and chemo‐
therapy. A retrospective study evaluated 146 patients who developed meningitis after
undergoing neurosurgery within 1 year. The most common organisms identified to cause the
infections were Staphylococcus epidermidis (28.1%); Staphylococcus hominis (11.0%); Staphylococ‐
cus haemolyticus (9.6%); Staphylococcus aureus (8.2%); and Enterococcus (8.2%). Propionibacter
acnes is another underappreciated gram‐positive anaerobe bacteria, which is commonly
associated with various types of implant‐associated infections including neurosurgical
shunts. With Propionibacter acnes belonging to the normal skin microbiota, it can easily cause
early shunt infections when theses microorganisms are introduced during surgery [2]. Gram‐
negative bacteria must also be considered in this type of infection with Klebsiella pneumoniae
(7.5%) being the most common, followed by Acinetobacter baumannii (2.1%), Pseudomonas
aeruginosa (1.4%), and Escherichia coli (1.4%). Empiric therapy should consist of a beta‐lactam
antibiotic that has adequate CNS penetration (i.e., cefepime, meropenem, or ceftazidime) in
addition to an agent that covers MRSA (i.e., vancomycin). The agents of choice for the treatment
of specific organisms are listed in Table 1, along with other common fungi known to cause
meningitis in the oncology critically ill patient.
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Organism Primary regimen Alternative regimen
Ampicillin susceptible
Enterococcus species
Ampicillin plus gentamicin –
Ampicillin resistant
Enterococcus species
Vancomycin1 plus gentamicin –
Enterococcus species Ampicillin and
Vancomycin resistant
Linezolid –
Escherichia coli and other Enterobacteriaceae Ceftriaxone or cefotaxime Aztreonam, Ciprofloxacin, meropenem,
SMX/TMP
Listeria monocytogenes Ampicillin or Pen G SMX/TMP,, meropenem
Methicillin susceptible
Staph aureus
Nafcillin or oxacillin Vancomycin1, meropenem
Methicillin resistant
Staph aureus
Vancomycin1 SMX/TMP, Linezolid
Staphylococcus epidermidis Vancomycin1 Linezolid
Streptococcus pneumoniae Penicillin MIC <0.1 µg/mL:
Pen G or ampicillin
0.1–1 µg/mL: ceftriaxone
or cefotaxime
≥2 µg/mL: Vancomycin1
+ ceftriaxone
or cefotaxime
Penicillin MIC <0.1 µg/mL:
ceftriaxone cefotaxime
0.1–1 µg/mL:, meropenem
≥2 µg/mL: moxifloxacin
Propionibacterium acnes Vancomycin1 plus cefepime
Vancomycin1 plus ceftazidime
Vancomycin1 plus meropenem
–
Pseudomonas aeruginosa Cefepime or ceftazidime Aztreonam, ciprofloxacin meropenem
PLUS
Aminoglycoside
Pen, penicillin; SMX/TMP, sulfamethoxazole/trimethoprim.
1 See vancomycin section for dosing.
Table 1. Agent of choice for bacterial meningitis based on culture identification [3, 4].
2.2. Catheter-associated urinary tract infections
Urinary tract infections (UTIs) are frequently encountered in oncology critically ill patients
due to frequent use of indwelling urinary catheters, urological procedures including ureteric
stent placements, neutropenia, and prolonged use of steroids. One hospital evaluated 115
patients with advanced cancer who had positive cultures in an eight (8)‐month period. As the
predominate infection, 61% of UTIs occurred in patients with indwelling catheters. Gram‐
negative organisms were the most common bacteria isolated, and patients receiving cortico‐
steroids had the highest rate of UTIs [5]. One study included 22 patients with malignancy and
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found in 57 original ureteric stents, 25 (44%) had bacterial colonization. Not all colonization
will lead to true UTIs. However, if the urine culture is positive or the leukocyte count is greater
than 30 on urinalysis, then antibiotic use and removal or change of the stent should be
considered due to stent colonization [6]. A lack of strong data exists for initiating prolonged
prophylactic antibiotics after stent placement to prevent such infections. Therefore, it is
important to treat based on whether the patient is symptomatic and an accurate diagnosis of
an active infection. Literature on empiric regimens, specifically in the oncology population, is
unavailable, and therefore, it is recommended a broad‐spectrum beta‐lactam antibiotic be used
with the addition of an antipseudomonal antibiotic if pseudomonas is suspected. Hemody‐
namically stable patients may be candidates for single‐agent therapy such as a fluoroquino‐
lone. Duration of therapy should be based on clinical response with therapy continued for 10–
14 days if response is delayed [7].
2.3. Post-obstructive pneumonia
Post‐obstructive pneumonia is frequently encountered in patients with cancer and can quickly
lead to ICU admission if symptoms become severe. This type of pneumonia is defined as a
“radiographic opacification resulting from complete or partial airway obstruction by a
pulmonary neoplasm” [8]. The findings can be a result of non‐infectious (mucus plugging,
parenchymal inflammation, or tumor) or infectious causes. Patients will often present with
severe cough, wheezing, and dyspnea, but these symptoms can be misleading making it
difficult to determine the need for antibiotic therapy. For example, patients may not have signs
of infection such as fever, chills, and leukocytosis and still have a microbe isolated. More
commonly, an infection is present if the patient has an infiltrate in addition to a fever [8]. The
majority of post‐obstructive pneumonias are polymicrobial caused by Haemophilus influenza,
Klebsiella pneumonia, Enterobacter cloacae, Acinetobacter species, Pseudomonas aeruginosa, Staphy‐
lococcus aureus, and Streptococcus viridans. Management of such infections requires treating the
source of obstruction through interventional bronchoscopy techniques in addition to antimi‐
crobial therapy. Until cultures are identified, a broad‐spectrum gram‐negative agent (i.e.,
cefepime) in addition to MRSA coverage should be initiated based on local susceptibility
patterns. Treatment should be considered for at least 7–10 days, similar to health‐care‐
associated pneumonias and based on patient’s clinical improvement.
2.4. Fever in the oncology patient
In both the critically ill and cancer patient, fever can be a common symptom not always
secondary to infection. Among 371 patients (477 episodes), fever was identified due to non‐
infectious causes in 23% of patients and due to unknown origin in 10% of patients [9].
Non‐infectious causes, independent of tumors, can be related to an allergic reaction, throm‐
boembolism, or an inflammatory disease. Cancer‐related fever is classically associated with
non‐Hodgkin’s and Hodgkin’s lymphoma, leukemia, and solid tumors [10]. A recent study
defined tumor fever as no microbiological, radiological, or clinical evidence of infection
and lack of response to empirical antimicrobial therapy for at least 7 days or experienced a
positive response to a naproxen test. Using this definition, the investigators evaluated the
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role of a procalcitonin (PCT) test for differentiating infectious from non‐infectious fever in
non‐neutropenic patients. The baseline PCT level was not different between those with tu‐
mor‐related fever and blood stream infections. However, there was a statistically significant
difference in the decrease in PCT levels between the two groups in response to antimicrobi‐
als suggesting one method for differentiating fever due to infectious versus non‐infectious
causes [11]. Other sources of fever which must be considered are chemotherapy (azathio‐
prine, hydroxyurea, interleukin‐2, rituximab, and interferon), transfusions, surgery, or pro‐
cedures [9, 10]. Drug‐induced fever is often overlooked and should be highly considered
especially if the fever resolves after stopping the expected culprit. Such medications in the
ICU that should be evaluated in the patient are antimicrobials, succinylcholine or inhaled
anesthetics antipsychotics possibly causing neuroleptic malignant syndrome, or antidepres‐
sants leading to serotonin syndrome [12]. Fever in these patients may not present in any
particular pattern, and signs of infection are attenuated due to the decreased inflammatory
response so fever tends to be the only sign of ensuing infection. Therefore, it is imperative
to identify fever associated with other symptoms such as rigors and chills to suggest an
infectious source and initiate appropriate targeted therapy.
2.5. Vancomycin dosing in oncology patients
Since the 1950s, studies have evaluated the pharmacokinetic (PK) and pharmacodynamic (PD)
profile of vancomycin to determine the best parameter that predicts its efficacy in clinical
practice. National guidelines provide broad recommendations, which should be applied as
the foundation for creating institution level policies [13]. However, they lack recommendations
specific to oncology patients, whose vancomycin PK is greatly altered when compared to the
general population. Furthermore, critically ill patients are subject to frequent alterations in
drug PK due to fluctuations in creatinine clearance, shifting of fluid leading to changes in
volume of distribution, decreased tissue perfusion, and decreased metabolism with organ
dysfunction all of which must be accounted for when dosing antibiotics. Several pharmaco‐
kinetic (PK) studies have shown an increased vancomycin volume of distribution (Vd) and
clearance (Cl) in cancer patients, requiring these patients to receive nearly double the average
dose than patients without cancer (60 vs. 30 mg/kg/day) to obtain therapeutic levels [14]. More
specific data with regards to cancer type or other patient factors contributing to these changes
have not been elucidated.
The PD parameter that best reflects clinical efficacy of vancomycin against S. aureus is
AUC/MIC with a target of ≥400 h [13, 15]. It has been proposed that 3–4 g of vancomycin per
day would be required for 90% probability of attaining an AUC/MIC of 400 h for an MIC of 1
mg/L and ≥5 g per day for vancomycin‐intermediate susceptible S. aureus (VISA) strains [13].
However, readily calculating the AUC/MIC is challenging and cannot easily be performed.
Subsequently, most clinical pharmacists have continued to use trough levels for determining
therapeutic concentrations. Therefore, until more efficient tools are available for applying
pharmacodynamics methods with AUC/MIC, it is suggested that multiple daily doses (three
or four as opposed to two with same total daily dose) may be preferred to achieve target
therapeutic levels in patients with hematologic malignancy and normal renal function [16]. In
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the critically ill patient, vancomycin can be also be effected by augmented renal clearance
(ARC) due to sepsis, trauma, autoimmune disorders, or major surgery. With AUC inversely
related to renal clearance, ARC can extensively impact the PK of vancomycin and lead to
subtherapeutic levels [17]. These combined factors in both oncology and critically ill patients
further support the need for possibly higher doses in this population.
2.6. Extended-infusion beta-lactam therapy
Studies have shown improvement in clinical outcomes (i.e., patient survival and duration of
hospitalization after onset of infection) by optimizing the pharmacodynamics with use of
extended‐infusion (EI) dosing regimens. The best predictor of bacterial killing for β‐lactams is
the time during which the free drug concentration exceeds the MIC of the organism (ƒT > MIC).
Near‐maximal β‐lactams bactericidal effect is typically observed when the free drug concen‐
tration exceeds the MIC for 50%, and 40% of the dosing interval for penicillins and carbape‐
nems, respectively [18–20]. With the increase in resistance among gram‐negative organisms,
optimizing activity of β‐lactam antibiotics through dosing strategies becomes crucial to
preserve clinical efficacy.
Of the most common β‐lactams used in critically ill oncology patients, piperacillin–tazobactam
and meropenem administered via extended infusion are associated with the most positive
clinical outcomes and have a higher probability of achieving target attainment. One retro‐
spective study assessed 194 patients who received 3.375 g IV every 4 or 6 h over a 30‐min
infusion, vs. 3.375 g IV every 8 h over a 4‐h infusion for treatment of P. aeruginosa infections.
Higher mortality and longer length of stay were seen with intermittent infusions (31.6% of
patients) compared to EI (12.2% of patients) in the more critically ill patients. Furthermore, the
Monte Carlo simulation showed the probability of target attainment (PTA) was only 20% with
intermittent infusion vs. 100% PTA with EI at an MIC of 16. With the MIC breakpoint for P.
aeruginosa to PTZ being ≤16/4, it is evident that intermittent infusions may not achieve optimal
levels to be efficacious [18].
Creatinine clearance (mL/min) Dose
Extended infusion
≥20 mL/min 3.375 g (30‐min infusion) × 1 dose STAT
Followed by 3.375 gm IV q8 h via 4 h infusion
<20 mL/min (including IHD/PD) 3.375 g (30‐min infusion) × 1 dose STAT, 3.375 g IV q12 h via 4 h infusion
CRRT 3.375 g (30‐min infusion) × 1 dose STAT, 3.375 gm IV q8 h via 4 h infusion
CRRT, continuous renal replacement therapy; PD, peritoneal dialysis; IHD, intermittent hemodialysis.
Table 2. Extended and conventional Piperacillin‐tazobactam dosing [22].
The use of loading doses prior to initiating extended infusion and time to exceeding the MIC
breakpoint has also been studied. A PK model demonstrated that 90% of the patients would
be expected to have PTZ and meropenem drug concentrations exceed the MIC breakpoint
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within 6 min if both agents were preceded by a loading dose versus 8 h and 36 min, respec‐
tively, without a loading dose [21]. Therefore, with sepsis guidelines providing evidence to
support a mortality benefit in administering antibiotics within 60 min for patients in septic
shock, a loading dose should be highly considered. Loading doses may be less important for
meropenem and susceptible organisms as optimal drug concentrations were achieved with
any regimen in no later than 36 min [21]. From the evidence outlined, the dosing regimens
for PTZ listed in Table 2 are recommended for critically ill oncology patients.
A retrospective, pre/post‐observation study of intermittent vs. extended‐infusion meropenem
was conducted in hematopoietic stem‐cell transplant patients and those treated with induction
chemotherapy for AML. Meropenem 1 g every 8 h via short 30‐min infusion (SI) was compared
with 1 g every 8 h via extended 4‐h infusion (EI). After 5 days of treatment, therapy was
successful in more cases in the EI group than the SI group (69.4 vs. 40.9%, p = 0.001) [23]. Various
meropenem regimens were also reviewed in a Monte Caro simulation. The probability of
achieving drug concentrations above the MIC for >40% of the dosing interval for Pseudomonas
aeruginosa were 87.9, 93.5, and 96.7% for doses of 500, 1000, and 2000 mg, respectively, and
thus, higher doses may be needed for immunocompromised patients with bacteria exhibiting
higher meropenem MICs (e.g., MIC >4 mg/L) [24]. Minimal evidence is available on the
appropriate dosage adjustments in renal failure. However, one study did evaluate the effects
of augmented renal clearance in critically ill patients on achieving target attainments with
extended‐infusion meropenem (1 g IV every 8 h via 3‐h infusion). Patients with a creatinine
clearance (CrCl) of 50 mL/min had a predicted probability of target attainment of approxi‐
mately 90% which inversely declined with increases in creatinine clearance (ƒT > MIC of ~50
and ~20% at CrCl of 100 and 150 mL/min, respectively). Therefore, critically ill patients who
commonly exhibit augmented clearance should have dosing regimens optimized whenever
feasible with lower doses possibly not considered until the CrCl is less than or equal to 50 mL/
min [25]. Consequently, we would recommend a regimen of meropenem 2 g IV every 8 h via
3‐h infusion for most critically ill oncology patients.
2.7. Treatment of multi-drug resistant organisms
As stated by the CDC, “antimicrobial resistance is one of our most serious health threats” [26].
The rate of infections caused by gram‐negative organisms continues to rise and significantly
contribute to morbidity and mortality worldwide [27]. First‐ and second‐line antibiotics are no
longer effective for such organisms, and thus, efforts to discover and approve new antimicro‐
bials continue to strengthen. The patient populations deemed to be most vulnerable to resistant
organisms are those receiving chemotherapy, recent hospital and intensive care unit admis‐
sion, and those with invasive devices. Due to their frequent exposure to antibiotics and
hospitalizations, risk of acquiring such organisms is significantly increased. Much of the data
for treatment of multi‐drug resistant organisms are based on case studies or retrospective
studies. The multitude of data concerning appropriate treatment options for all multi‐drug
resistant organisms exceeds the capacity of this chapter. Therefore, primary and secondary
regimens for only CRE and ESBL organisms have been described in Tables 3 and 4.
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Infection Regimen options
UTI Ceftazidime/avibactam 2.5 g IV q8 h
Fosfomycin One packet (3 grams) orally q2 to 3 days for 3 doses (can be extended
to 21 days in some cases)
Meropenem IV 2 g q8 h (3‐h infusion)3 plus
Ertapenem 1 g IV q24 h (1 h after meropenem)
Colistin IV1,2,4 plus Meropenem 2 g q8 h (3‐h infusion)3
Bacteremia Colistin IV2,4 plus Meropenem IV 2 g q8 h (3‐h infusion)3
Polymixin B2 plus Meropenem 2 g IV q8 h (3‐h infusion)3
Intra-abdominal Ceftazidime/avibactam 2.5 g IV q8 h plus Metronidazole 500 mg IV q8 h
Colistin IV2,4 plus Meropenem 2 g q8 h (3 h infusion)3
Polymixin B2 plus Meropenem 2 g IV q8 h (3 h infusion)3 plus
Tigecycline 200 mg IV loading dose then 100 mg IV q12 to 24 h if
meropenem MIC >16 mcg/mL and polymyxin B MIC >2 mcg/mL
ASSSI Tigecycline 200 mg IV loading dose then 100 mg IV q12 to 24 h plus Polymixin B2
plus Meropenem 2 g q8 h (3‐h infusion)3
ASSSI, acute skin/skin structure infection; UTI, urinary tract infection.
1 Colistin IV is recommended over Polymixin B for treatment of urinary tract infections based on pharmacokinetic
properties. Urinary concentrations of Polymixin B remain low compared to Colistin due to Polymixin B is eliminated
primarily by non‐renal mechanisms.
2 Refer to references [33] and [96] for appropriate dosing.
3 Monitor patient closely for development of seizures with high‐dose carbapenems.
4 Not recommended for organism with MIC ≥4.
Table 3. Regimens for treatment of CRE by site of infection [25, 28–33].
Antimicrobial Comments
Carbapenem (imipenem,
meropenem, ertapenem)
First‐line agents
Ceftolozane/tazobactam Only indicated for treatment of complicated intra‐abdominal infections and
complicated urinary tract infections including pyelonephritis (in vitro data)Ceftazidime/avibactam (add
Metronidazole for intra‐
abdominal infections)
Tigecycline Only indicated for treatment of complicated skin and skin structure infections,
complicated intra‐abdominal infections, and community‐acquired pneumonia
Limited penetration in urinary tract and blood
β‐lactam/β‐lactamase inhibitor
combinations (amoxicillin‐
clavulanate, piperacillin–
tazobactam, ampicillin‐
sulbactam)
Such agents should be reserved for treatment of ESBL organisms from the urinary
tract with poor efficacy data for other sites of infections due to these organisms
Colistin High‐risk for renal toxicity
Fosfomycin IV formulation not available in the USA
Oral formulation only indicated for UTI
Table 4. Antimicrobial therapy regimens for treatment of extended‐spectrum beta‐lactamases (ESBL) [34–36].
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2.8. Clostridium difficile infection (CDI)
The rates of CDI continue to increase exponentially with strains becoming more virulent and
difficult to treat in addition to more patients becoming colonized. Oncology patients, especially
those with hematological malignancies, are particularly susceptible due to multiple risk factors
such as frequent and prolonged hospitalizations, exposure to multiple courses of antibiotics,
and chemotherapeutic agents. It has even been proposed that chemotherapeutic agents
without concomitant antibiotics have been associated with CDI. Such incidences are most
commonly reported to be caused by methotrexate and 5‐FU. Methotrexate is suspected to cause
severe disruption of intestinal protein metabolism causing a pronounced inflammatory
cytokine response and promoting CDI. Similar effects have been seen due to irinotecan and
topotecan; thus, clinicians should monitor for signs of CDI even after chemotherapy admin‐
istration. Appropriate diagnostic work‐ups with combination testing (i.e., glutamate dehy‐
drogenase followed by confirmatory testing with enzyme immunoassay and quantitative real‐
time PCR) should be performed to differentiate between colonization and true infections
(Figures 1 and 2) [95].
Figure 1. Diagnosis and Treatment of CDI.
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Figure 2. Appropriate C.difficile Testing and Interpretation.
2.9. Intra-abdominal infections
Intra‐abdominal infections in cancer patients are especially common following surgery. One
of the high‐risk procedures being performed in several oncology centers is hyperthermic
intraperitoneal chemotherapy (HIPEC) which can be associated with severe complications
such as peritonitis. These patients are often transferred to the ICU for post‐op monitoring and
thus the ICU becomes the unit where such infections are managed. A retrospective study noted
9% of 52 patients required reoperation for post‐operative peritonitis following complete
cytoreductive surgery (CCRS) combined with HIPEC. The infections were most frequently
caused by E. coli in 5 samples (71%) and Enterobacter species in two samples (29%), with seven
of the nine bacteriological species being multi‐drug resistant. Unfortunately, this is only one
of the many intra‐abdominal infections these patients can experience.
In the elderly population (>65 years), it was noted that the spectra of diseases that cause intra‐
abdominal sepsis are different from younger populations. The most common types in the
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elderly were diverticulitis, cholecystitis, cholangitis, and perforation of the colon from
obstructing adenocarcinoma. Advanced tumors leading to perforation and then abscesses or
peritonitis have been reported as frequently as 2.6–10%. This can quickly lead to severe sepsis
or septic shock that requires management in the ICU. The common offending organisms
identified are those of the gastrointestinal tract, Enterococcus species, Candida species, Staphy‐
lococcus epidermidis, E. coli, Enterobacter species, B. fragilis, and Pseudomonas species [40]. There
are no guidelines available for recommendations on antimicrobial therapy specific to critically
ill oncology patients, and therefore, it is recommended that combination therapy is initiated
with a broad‐spectrum agent with anaerobic coverage, a second gram‐negative agent with
activity against Pseudomonas aeruginosa if suspected, and an antifungal agent with activity
against Candida glabrata.
Per IDSA guidelines, it is recommended that intravenous (IV) metronidazole is added to vanco‐
26mycin oral only in the “severe, complicated” cases defined by hypotension, shock, the
presence of an ileus, or megaco‐27lon, and not in “severe” cases (white blood cell (WBC) count
of ≥15,000 cells/mL or serum creatinine ≥1.5 times base‐28line) [37]. A recent retrospective,
observational study evaluated mortality amongst critically ill patients who received 29 oral
vancomycin vs. oral vancomycin with IV metronidazole defined by primarily clinical criteria.
A total of 88 pa?30tients were evaluated including 23 immunocompromised patients. Mortality
were found to be significantly better in31the combination therapy group, compared to the
monotherapy group (36.4 vs. 15.9%, p = 0.03). This suggests the need32to further consider the
true definition of “severe disease” vs. “critically ill” and whether selection of therapy should
be33based on clinical criteria in addition to laboratory data. The study design cannot defini‐
tively provide support for all34critically ill patients receiving combination therapy; however,
it does propose that IV metronidazole in addition to van‐35comycin should be considered in
the most severely ill patients [38]. Per IDSA guidelines, it is recommended that intravenous
(IV) metronidazole is added to vanco‐26mycin oral only in the “severe, complicated” cases
defined by hypotension, shock, the presence of an ileus, or megaco‐27lon, and not in “severe”
cases (white blood cell (WBC) count of ≥15,000 cells/mL or serum creatinine ≥1.5 times base‐
28line) [37].
The administration of probiotics is also a common topic amongst patients who are on pro‐
longed antibiotic2therapy for primary or secondary prevention of C. difficile. As IDSA
guidelines recommended in 2010, there are limited3data to support its use and potential risk
for bloodstream infections [37]. A report released by the World Health Organ‐4ization (WHO)
noted probiotics may be theoretically responsible for four types of side effects: (1) systemic
infections,5(2) deleterious metabolic activities, (3) excessive immune stimulation in susceptible
individuals, and (4) gene transfer.6There have been several case reports of infections caused
by organisms consistent with probiotic strains including but7not limited to Saccharomyces
boulardii, Lactobacilli, Lactobacillus acidophilus, and Lactobacillus casei [39]. Due to the use
of8probiotics remaining controversial and with the lack of clinical trials to confirm the safety
of these products, clinicians9are advised to remain cautious when using such products in
immunocompromised patients, including those started on 10 corticosteroids, which is
common in ICU patients [39].
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Empiric regimens for necrotizing fasciitis
Primary regimen Alternative regimen
Piperacillin–tazobactam extended infusion
(preferred) or intermittent infusion plus
vancomycin1
Levofloxacin plus (clindamycin or metronidazole) plus aminoglycoside
Imipenem‐cilastatin
Meropenem
Ertapenem
Cefotaxime plus metronidazole or
clindamycin
Regimens based on culture data
Streptococcus Penicillin plus clindamycin
Clostridium species
Aeromonas hydrophila Doxycycline plus (ciprofloxacin or ceftriaxone)
Vibrio vulnificus Doxycycline plus (ceftriaxone or cefotaxime)
Gram‐negative organisms Based on local susceptibility (Carbapenem for ESBL‐producing
organisms)
1 See vancomycin section for dosing.
Table 5. Treatment regimens for necrotizing fasciitis [44].
2.10. Skin and soft tissue infections
Chemotherapy, radiation, and multiple surgical procedures place oncology patients at risk
for developing skin and soft tissue infections. One particularly lethal skin infection that re‐
quires immediate transfer to the ICU is necrotizing fasciitis (NF) which has been more com‐
monly associated with certain debilitating conditions such as immunosuppression. No true
risk factors have been delineated, and the cause of ≥20% of necrotizing soft tissue infections
is idiopathic making it challenging to determine precipitating factors. The onset and pro‐
gression of signs and symptoms are rapid especially with Group A Streptococcus or Clostridi‐
um making it crucial that both surgical intervention and antibiotic intervention are
considered immediately when suspecting NF [41]. In a retrospective review with 8534 hem‐
atological malignancy patients, nine (9) were diagnosed with NF. Interestingly, pathogens
isolated were all gram‐negative organisms (Salmonella, Vibrio vulnificus, Aeromonas, ESBL
Klebsiella, ESBL Escherichia coli, and Enterobacter cloacae) [42]. Another case report was pub‐
lished of a febrile neutropenia patient with myelodysplastic syndrome (MDS) that experi‐
enced a blunt injury to the left upper extremity. This resulted in rapid progression of the
wound with fluid accumulation that extended from the left upper arm to the proximal medi‐
al forearm. All blood cultures revealed S. maltophilia, and the patient was treated both surgi‐
cally and with IV trimethoprim/sulfamethoxazole [43]. Although group A Streptococcus has
Oncology Critical Care46
most commonly been known as the leading cause of NF, more than one retrospective review
has identified gram‐negative NF associated with malignancy making it imperative for clini‐
cians to consider broad‐spectrum antibiotics that adequately cover for possible resistant or‐
ganisms as shown in Table 5 [42].
Another common skin infection in oncology patients known to be closely related to lymphe‐
dema is cellulitis. Unfortunately, every incidence of cellulitis can further damage the lymphatic
system which in turn leads to secondary episodes of lymphedema. Due to the protein‐rich
lymphatic fluid which accumulates due to impaired drainage, bacteria can easily invade such
areas and cause local cellulitis infections. Therapy should be directed at likely organisms
such as streptococcus and patients with three to four episodes per year of recurrent cellulitis
should be considered for prophylactic antibiotics (~4–52 weeks) [44, 45]. As suggested by IDSA
guidelines, non‐purulent soft tissue skin infections in immunocompromised patients are
categorized as “severe” and should be considered for broader therapy with piperacillin–
tazobactam plus vancomycin [44]. Purulent skin and soft tissue infections should undergo
incision and drainage with the addition of antibiotics (Figure 3).
Figure 3. Treatment Algorithm of Recurrent Episodes.
The ideal treatment options for the numerous infections that oncology critical care patients
encounter have yet to be defined. Subsequently, therapy should always be optimized with
respect to pharmacokinetic and pharmacodynamic properties of antimicrobials when regi‐
mens are selected. It is also well understood that therapy is often most aggressive in the
immunocompromised and severely ill population. Therefore, side effects and toxicities of all
agents must be weighed against efficacy to ensure safety is not compromised.
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3. Prophylactic and therapeutic anticoagulation
3.1. Epidemiology
It is well known that the risk of thrombosis in oncology patients far exceeds the risk encoun‐
tered by those without a cancer diagnosis. Thrombosis accounts for 10% of fatal events in
oncology patients, making it the second leading cause of death in this patient population.
Patients with cancer experience between a twofold to 20‐fold increased risk of developing
venous thromboembolism (VTE), which is most likely to occur within the first six months of
cancer diagnosis [46, 47]. Patients diagnosed with cancer of the pancreas, stomach, colon, brain,
lung, and ovaries are at higher risk of developing VTE in addition to treatment with antian‐
giogenic agents, such as thalidomide and lenalidomide used in multiple myeloma [46–49].
Unfortunately, this VTE risk is only further exacerbated in critically ill ICU patients. It has been
noted that the incidence of deep venous thrombosis ranges from 28 to 32% in general medical
ICU patients with nearly 95% being clinically silent [50]. One single‐center prospective cohort
identified four risk factors for ICU‐acquired VTE including personal or family history of VTE,
end‐stage renal failure, platelet transfusion, and vasopressor use [51]. Catheters may be subject
to thrombotic events, leading to pulmonary embolism in 10–15% of patients and loss of access
in 10% of patients [52]. Such complications place a patient in danger of the effects of VTE and
impede cancer‐directed therapy, enabling progression of the disease.
Not only do VTEs affect a patient’s cancer prognosis, but they also increase the risk of com‐
plications, such as bleeding, which is 2.5 times more likely to occur in oncology patients
receiving anticoagulant therapy within the first year of VTE [46, 48]. Unfortunately, this does
not preclude patients from being at risk for recurrence of thrombosis during anticoagulant
therapy. Thrombosis during anticoagulant therapy occurs in 6–17% of cancer‐related VTE,
nearly three times higher than in non‐oncology patients with a history of thromboembolism
[46–48]. Given the increased risk of VTE in oncology patients contributing to morbidity and
prolonged hospitalizations, it is important to adequately understand the options available for
treatment and the recommended guidelines for the use of such medications in an oncology
population.
3.2. Thromboprophylaxis and first-line treatment
Several well‐published guidelines provide recommendations for prophylaxis and treatment
of thrombosis in oncology and ICU patients, all of which have slightly different suggestions
for appropriate therapy. Thus, it was necessary to provide summaries for several of these
publications to allow clinicians to consider multiple view points and make the best clinical
decision. Recommendations only applicable to the critically ill oncology population are
provided for thromboprophylaxis, treatment of established VTE, and recurrence manage‐
ment in Tables 6–8. Additionally, per CHEST guidelines, mechanical prophylaxis alone should
be considered only in ICU patients at high risk of bleeding with pharmacologic agents resumed
when such bleeding risks are resolved [55]. Combination of pharmacologic and mechanical
modalities should be considered in all patients as a meta‐analysis published in the Cochrane
Library suggested the combination was superior to either alone [58].
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Criteria Prophylaxis options
Non-surgical
General ICU or hospitalized patients with active
malignancy
and acute medical illness or reduced mobility. (Not
routinely recommended for patients admitted for
minor procedures, short chemotherapy infusion, or
patients undergoing stem‐cell/bone
marrow transplantation)
Unfractionated heparin 5000 units SQ q8 h
Dalteparin 5000 SQ units daily
Enoxaparin 40 mg SQ daily
Fondaparinux 2.5 mg SQ daily
Surgery
All patients with malignant disease undergoing major
surgical intervention unless contraindicated because
of active bleeding or high bleeding risk.
Unfractionated heparin 5000 units 2–4 h preoperatively and
once q8 h thereafter or 5000 units 10–12 h preoperatively and
5000 units twice daily thereafter
Prophylaxis should be continued for at least 7–10
days in patients undergoing major surgery, and up to
4 weeks in patients receiving major abdominal and
pelvic surgery with high‐risk factors such as restricted
mobility, obesity, history of VTE, or with additional
risk factors noted in ASCO guidelines.1
Dalteparin 2500 units SQ 2–4 h preoperatively and 5000 units
SQ daily thereafter or 5,000 units SQ 10–12 h preoperatively
and 5000 units SQ once daily thereafter
Enoxaparin 20 mg SQ 2–4 h preoperatively and 40 g daily
thereafter or 40 mg SQ 10–12 h preoperatively and 40 mg SQ
once daily thereafter
LMWH or UFH commenced Fondaparinux 2.5 mg SQ daily beginning 6–8 h post‐
operatively
Post‐operatively for the prevention of VTE in
oncology patients undergoing neurosurgery.
Additional recommendations for when to initiate prophylactic
therapy post‐surgery is available through NCCN guidelines
UFH, unfractionated heparin; LMWH, low molecular weight heparin; VTE, venous thromboembolism; SQ,
subcutaneous.
1 Multiple risk assessment models have been proposed but yet to be validated before strong recommendations are
made for inpatient screening. ASCO guidelines should be referenced for predictive models.
Table 6. Thromboprophylaxis [52–56].
Criteria Treatment options
LMWH is preferred over UFH for the initial 5–10 days
of anticoagulation for VTE in patients without
renal impairment (CrCl <30 mL/min)
Unfractionated heparin 80 units/kg IV bolus, then
18 U/kg per h IV; adjust dose based on aPTT
Dalteparin 100 units/kg SQ q12 h or 200 units/kg SQ daily
Enoxaparin 1 mg/kg SQ q12 h or 1.5 mg/kg daily
Fondaparinux <50 kg: 5 mg SQ daily
50–100 kg: 7.5 mg SQ daily
>100 kg: 10 mg SQ daily
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Criteria Treatment options
For long‐term anticoagulation (at least 6 months),
LMWH is preferred over VKAs (VKA is acceptable if
LMWH is not available)
Dalteparin 200 units/kg SQ daily for 1 month, then 150
units/kg SQ daily
Consider anticoagulation beyond 6 months for
patients with active cancer (metastatic disease) or
those receiving chemotherapy
Enoxaparin 1.5 mg/kg SQ daily or 1 mg/kg once q12 h
For catheter‐associated thrombosis, anticoagulate as
long as the catheter is in place for at least 3 months
Warfarin Adjust dose to maintain INR 2–3
Consider insertion of vena cava filter in patients with contraindications to anticoagulant therapy or as adjunct to
anticoagulation in patients with progression of thrombosis.
Use of novel oral anticoagulants for either prevention or treatment of VTE in patients with cancer is not formally
recommended by national guidelines at this time.
CrCl, creatinine clearance; UFH, unfractionated heparin; LMWH, low molecular weight heparin; VKA, vitamin K
antagonist; VTE, venous thromboembolism.
Table 7. Treatment of newly established VTE [52–54, 57].
Treatment patient was receiving
when recurrence of VTE
diagnosed   
Secondary treatment options
VKA LMWH6 or fondaparinux or UFH
LMWH Increase the dose of LMWH dose in patients treated with LMWH
Consider twice daily dosing if patient experiences recurrent VTE while
receiving once‐daily dosing of LMWH
UFH LMWH or fondaparinux
Increase dose of UFH
Failure of any agent Consider placement of an inferior vena cava filter
UFH, unfractionated heparin; LMWH, low molecular weight heparin; VKA, vitamin K antagonist; VTE, venous
thromboembolism.
Table 8. Treatment of VTE recurrence in oncology patients receiving anticoagulation [52, 54].
3.3. Direct oral anticoagulants (DOACs)
Alternatives to treatment include new, direct oral anticoagulants (DOACs) dabigatran,
rivaroxaban, apixaban, and edoxaban. Limited research has been conducted on their use in
patients with cancer and the critically ill population [47]. While the standard approach to
treating VTE is currently with use of LMWH or fondaparinux followed by warfarin, DOACs
simplify anticoagulation therapy as they are administered in fixed doses and do not require
routine monitoring [59, 60]. Warfarin therapy, though effective, is accompanied by burdensome
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disadvantages, including constant monitoring due to the small therapeutic window and
multiple drug interactions [60]. Large clinical trials have proven the DOACs to be non‐inferior
to LMWH/warfarin therapies in efficacy, are associated with fewer bleeding events, and have
fewer food/drug interactions [60, 61]. Although the Food and Drug Administration (FDA) has
approved rivaroxaban, apixaban, dabigatran, and edoxaban in the USA, the use of DOACs is
not formally recommended in oncology patients due to limited clinical data [61]. Furthermore,
the use of DOACs especially in ICU should be considered only for those patients who are
clinically stable and are not scheduled to have a procedure in the ICU. Despite the lack of
randomized trials, many clinicians are beginning to incorporate such oral agents into long‐
term treatment options for oncology patients due to their ease of administration compared to
warfarin and LMWH.
Rivaroxaban is a direct factor Xa inhibitor and was the first DOAC approved by the FDA in
2012 [61–63]. It is contraindicated with inhibitors of CYP3A4 and P‐glycoprotein including
ketoconazole and ritonavir due to increased plasma drug concentrations [62]. Two non‐
inferiority studies that included patients with cancer, proved rivaroxaban equally as effective
as LMWH/warfarin therapy with similar rates of bleeding [61, 63]. Recurrent VTE occurred in
3.4% of oncology patients treated with rivaroxaban compared to 5.6% of oncology patients
with enoxaparin/VKA therapy [63]. One concern with rivaroxaban in critically ill oncology
patients is that doses of 15–20 mg must be taken with food to optimize bioavailability. This is
often difficult in an oncology population known to have poor appetites and inadequate oral
intake. The tablets can be crushed and administered via nasogastric feeding tubes; however,
administration via this route must be followed by enteral feedings to optimize absorption.
Furthermore, administration through feed tubes placed distal to the stomach will decrease
absorption of rivaroxaban [63].
Apixaban, a direct factor Xa inhibitor, was approved by the FDA in 2014 [61]. Similar to
rivaroxaban, apixaban is contraindicated with CYP3A4 inhibitors due to increased plasma
drug concentrations [62]. In the double‐dummy, double‐blind AMPLIFY trial, apixaban was
proven non‐inferior compared to standard anticoagulation therapy (LMWH/warfarin) for
incidence of recurrent VTE, and major bleeding events occurred less frequently with apixaban
[61]. In the AMPLIFY‐EXT trial, long‐term anticoagulation for approximately 1 year with
apixaban was evaluated in patients who had already been treated for DVT and/or PE for six
to 12 months. Compared to placebo, apixaban was superior in preventing recurrent VTE and
all‐cause death. One additional compelling study evaluating patients with non‐valvular atrial
fibrillation was able to prove that apixiban 5 mg twice daily compared to aspirin 81–324 mg
daily showed significant reduction in stroke and systemic embolism in addition to lower rates
of bleeding. The AMPLIFY and AMPLIFY‐EXT included a small portion of oncology patients
(3.1 and 1.7%, respectively) in which recurrent VTE and major bleeding events occurred about
half as frequently in the apixaban group compared to oncology patients treated with enoxa‐
parin/warfarin [64]. Apixaban is further advantageous in ICU patients at risk of multi‐system
organ failure as it does not require renal or hepatic dosage adjustments.
Dabigatran, a direct thrombin inhibitor, was approved by the FDA in 2014 [61]. Dabigatran
proved non‐inferior in efficacy and had similar bleeding risks compared to warfarin in the
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double‐blind, double‐dummy RE‐COVER and RE‐COVER II studies [61]. When compared to
enoxaparin, rivaroxaban, and apixaban, efficacy was similar but bleeding risks were signifi‐
cantly higher with dabigatran. A meta‐analysis comparing trials of these DOACs found that
major bleeding risk was lower in those using apixaban than users of dabigatran and edoxaban
[65]. Aside from the higher bleeding risk, clinicians should be cautious with its use in the
oncology setting as it has a long half‐life and requires discontinuation of therapy at least 1–2
days prior to surgery or even as early as 3–5 days for those with a CrCl <50 mL/min. The oral
anticoagulant is not recommended for most indications in patients with a CrCl <30 mL/min
and must be adjusted if administered with specific P‐gp inhibitors. Due to multiple safety risks,
the use of dabigatran in the oncology setting has fallen out of favor and caution is advised
when treating patients who arrive to the ICU on chronic dabigatran therapy.
Few national guidelines have incorporated these agents into recommendations for treating
VTE; however, a recent meta‐analysis of five randomized controlled trials did prove that
DOACs are comparable to VKA (warfarin) therapy in treating cancer‐related VTE, which
makes this class of anticoagulants promising in the future [61]. Unfortunately, the DOACs still
face one major concern: managing real‐world DOAC‐associated bleeding, as no antidote is
currently FDA‐approved for these agents. Some guidelines make recommendations for
managing DOAC‐associated bleeding events, but the principles are based on laboratory, not
clinical parameters [60]. Further research is needed to validate the use of DOACs in VTE
treatment, especially in an oncology population.
3.4. Bleeding and thrombocytopenia
Thromboprophylaxis significantly reduces the rate of symptomatic VTE and is important for
improving the quality of life in oncology patients, but it is associated with an increased risk of
bleeding especially in ICU patients with coagulopathies abnormalities from sepsis and organ
failure [48]. In patients with a high risk of bleeding who experience acute proximal DVT or PE,
anticoagulation therapy may not be appropriate. The American College of Chest Physicians
(ACCP) advises placing an IVC filter in this situation [61].
One common risk for bleeding in oncology critically ill patients is thrombocytopenia secondary
to chemotherapy, blood loss during surgery, toxins including other drugs, macrophage‐
activation syndrome, disseminated intravascular coagulopathy, and massive transfusions.
Anticoagulation therapy should be pursued if the platelet count remains above 50 ×109, and
platelet transfusions should be considered during the high‐risk period of recurrence in order
to provide full anticoagulation therapy. Furthermore, it is crucial to delineate whether the cause
of thrombocytopenia is related to consumptive coagulopathy that can continue to worsen over
several days or if the decrease in platelets is only an acute change due to a single event such
as surgery, which is likely to resolve quickly [66]. This approach can help determine the
appropriate course of action such as reducing the dose of LMWH by 50% if the platelet count
is between 25 and 50 × 109 and cannot be sustained by transfusions or if all anticoagulants
should be held with the risk of bleeding exceeding the risk of clotting [47].
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4. Adverse effects of anticancer therapy leading to emergent ICU
admissions in the adult population
Patients with malignancies are at risk for acute life‐threatening illnesses that require intensive
care unit (ICU) admission. Leukemia and lymphoma are the most common hematologic
cancers encountered in the ICU, and lung cancer is the most common solid tumor encountered
in adults [67]. In addition, as many as 40 percent of allogenic hematopoietic cell transplant
(HCT) recipients develop one or more complications where transfer to the ICU is necessary
[68]. Indications for ICU admission in oncology patients include decompensation secondary
to progression of the cancer, treatment‐related side effects, or comorbid illnesses.
Patients whose survival rates remain marginally low include allogeneic bone marrow trans‐
plant recipients with severe GVHD unresponsive to immunosuppressive therapy, patients
with multiple organ failure related to delayed ICU admission, and specific clinical vignettes
in patients with solid tumors [69]. They are exposed to individual or combination chemother‐
apy regimens with the intention of cure or remission but not without risk for developing acute
or long‐term side effects requiring escalation of care. The following are only a few of the many
anticancer therapy‐related AEs, and oncology patients may experience resulting in ICU
admission.
4.1. Tumor lysis syndrome (TLS)
TLS is an oncologic emergency caused by massive tumor cell lysis with the overwhelming
release of intracellular contents (potassium, phosphorus, and nucleic acids) into the systemic
circulation. In turn, the kidneys are overwhelmed due to the rapid influx of these contents and
inability to excrete them efficiently. This can cause potentially life‐threatening metabolic and
electrolyte abnormalities which can require a patient to be transferred to an ICU for more
appropriate management [70]. The four key electrolyte abnormalities are hyperuricemia (uric
acid >8 mg/dL), hyperphosphatemia (phosphate >4.5 mg/dL), hypocalcemia (total serum
calcium <7 mg/dL), and hyperkalemia (>6 mmol/L).
TLS manifestations may occur before initiation of chemotherapy but are usually observed
within 12–72 h after therapy begins and may persist for 5–7 days post‐therapy. TLS occurs most
frequently after the initiation of cytotoxic therapy in patients with highly aggressive lympho‐
mas (Burkitt subtype) and acute lymphoblastic leukemia (ALL). TLS may also occur sponta‐
neously and/or in other tumor types that have high proliferation rate, large tumor burden
(reflected by serum lactate dehydrogenase levels), or high sensitivity to cytotoxic therapy.
Common anticancer agents associated with TLS are listed in Table 9.
The Cairo‐Bishop grading system is used to classify and grade TLS. TLS is diagnosed by
Laboratory Tumor Lysis Syndrome (LTLS) or by Clinical Tumor Lysis Syndrome (CTLS). A
retrospective analysis of 772 consecutive acute myeloid leukemia (AML) patients receiving
induction chemotherapy concluded clinical TLS (not laboratory) was associated with a
significantly higher risk of death during induction therapy (30 out of 38 patients; 79 vs. 23%
of those patients without evidence of clinical TLS) [70]. The risk for developing TLS is stratified
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as low, intermediate, and high risk with treatment strategies varying by each level of risk
shown in Table 10. Those in the high‐risk category strongly need aggressive intervention, and
those in the low‐risk category might need only observation, but the classification and treatment
approach for the intermediate‐risk patients is not as clearly defined.
Continuous hydration is the cornerstone of TLS prevention and is recommended prior to
therapy in all patients that fall into the intermediate‐ or high‐risk category. The goal is to
improve renal perfusion, to improve glomerular filtration rate, and to produce a high urine
output to lessen the likelihood of uric acid or calcium phosphate from precipitating in the renal
tubules. It is imperative to use cautiously in patients with underlying kidney injury or cardiac
dysfunction. The following are key points of this section [72–76]:
• Begin continuous hydration ideally 2 days before chemotherapy is to be given. Continue
therapy during chemotherapy administration and 2–3 days after chemotherapy completion.
Vigorous hydration (intermediate and high risk) consists of 2–3 L/m2/day IV solution
consisting of 0.225%NS + D5W, with a urine output goal of 80–100 mL/h
• To enhance renal excretion, consider furosemide 20–40 mg IV push to maintain urine output
>100 mL/m2/h or 2 mL/kg/h. Diuretic use is contraindicated if the patient has evidence of
acute obstructive uropathy or hypovolemia. Potassium must also be closely monitored due
to furosemide’s ability to increase renal excretion of this electrolyte.
• The role of urinary alkalization with either acetazolamide and/or sodium bicarbonate is a
controversial issue; therefore, use of sodium bicarbonate is only indicated in patients with
metabolic acidosis [70].
Bendamustine Ibrutinib
Bortezomib Imatinib
Brentuximab Vedotin Lenalidomide
Carfilzomib Mechlorethamine
Cetuximab 6‐Mercaptopurine
Cisplatin Nilotinib
Cytarabine Obinutuzumab
Dasatinib Omacetaxine
Daunorubicin Paclitaxel
Doxorubicin Rituximab
Epirubicin Romidepsin
Etoposide Thalidomide
Fludarabine Vincristine
Table 9. Anticancer agents associated with tumor lysis syndrome (TLS) [71].
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Risk category1 Treatment options
Low‐risk patients • Observation
• Normal hydration with IV fluids
• Monitor laboratories once daily throughout chemotherapy, then as clinically indicated post‐
treatment manage fluid and electrolyte abnormalities
• +/− Allopurinol
Intermediate‐risk
patients
• Vigorous hydration and inpatient monitoring
• Initiate allopurinol or rasburicase if uric acid >7.5 mg/dL (Some practices report administering a
single dose of rasburicase in this setting, which is a reasonable alternative)
• Monitor laboratories every 8–12 h throughout chemotherapy, then as clinically indicated post‐
treatment
• Initiate rasburicase
High‐risk patients • Increase hydration and maintain urine output
• Cardiac monitoring
• Initiate rasburicase for 1 dose and repeat only if uric acid ≥7.5 mg/dL
• Monitor laboratories every 6–8 h throughout chemotherapy, then every 1–2 days post‐treatment
and as clinically indicated
• Manage fluid and electrolyte abnormalities
• Consult nephrology
Established TLS in
patients
• Admission to Intensive Care Unit
• Increase hydration and maintain urine output
• Cardiac monitoring
• Initiate rasburicase for 1 dose and repeat only if uric acid ≥7.5 mg/dL
• At the end of rasburicase treatment, patients should start allopurinol
• Monitor laboratories every 4–6 h daily
S/S, signs and symptoms; IVP, intravenous push; CrCl, creatinine clearance; IV, intravenous; NS, normal saline; D5W,
5% dextrose in water; G6PD, glucose‐6‐phosphate dehydrogenase deficiency; WBC, white blood cells.
1 Refer to reference [73] for definitions and criteria defining low‐, intermediate‐, and high‐risk patients.
Table 10. Tumor lysis syndrome (TLS) treatment based on risk stratification [72–75].
Allopurinol is a xanthine oxidase inhibitor, which means it blocks the enzyme responsible for
the conversion of xanthine to uric acid. Allopurinol is preferred for patients that fall into the
low‐risk category explained in Table 10. It is recommended to start 1–2 days prior to initiating
chemotherapy to prevent excess uric acid, but it will not reduce uric acid levels in patients who
have existing hyperuricemia [77]. Unfortunately, the excess xanthine levels could precipitate
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into the kidneys leading to the renal dysfunction. Another limitation of allopurinol is it
interferes with the excretion of other chemotherapy agents (high‐dose methotrexate, cyclo‐
phosphamide, mercaptopurine, and azathioprine). If concomitant use cannot be avoided,
reduce 6‐mercaptopurine and/or azathioprine doses by 65–75% when used with allopurinol
[78]. Allopurinol should never be administered with capecitabine because it may decrease its
effectiveness [71]. The recommended oral allopurinol dose per the manufacturer is 600–800
mg daily in divided doses or 100–300 mg oral every 8 h daily (maximum of 800 mg/day).
Alternative dosing (off label for intermediate risk for TLS) is 10 mg/kg/day divided every 8 h
(maximum of 800 mg per daily) or 50–100 mg/m2 every 8 h (max dose 300 mg/m2 daily)
beginning 1–2 days before initiation of chemotherapy induction. This may be continue for 3–
7 days after chemotherapy [74 ]. IV allopurinol can be used in patients not tolerating oral at a
dose of 200–400 mg/m2/day in one to three divided doses (maximum of 600 mg/day) beginning
1–2 days before initiation of chemotherapy induction and may be continued for 3–7 days after
chemotherapy [78]. Allopurinol should be continued until uric acid levels are normalized and
tumor burden, WBC count, and other laboratory values have returned to low TLS risk levels
as defined in Table 10. Refer to Table 11 for appropriate renal adjustments.
Creatinine Clearance (ml/min) Daily Oral Allopurinol Dose
Manufacturer Recommended Allopurinol Dosing [78]
10–20 200 mg
<10 100 mg
<3 100 mg at extended intervals
(more than 24 h if necessary)
Alternative Allopurinol Dose Adjustments [74]
140 400 mg
120 350 mg
100 300 mg
80 250 mg
60 200 mg
40 150 mg
20 100 mg
10 100 mg every 2 days
0 100 mg every 3 days
CrCl, creatinine clearance.
Table 11. Recommended allopurinol dosing.
Rasburicase is a recombinant urate oxidase produced by a genetically modified S. cerevisiae
strain. Rasburicase is used to treat hyperuricemia by converting uric acid to allantoin thereby
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reducing uric acid levels and helping to control serum potassium, phosphorus, calcium, and
creatinine levels [70]. Allantoin is highly effective with it being five to ten times more soluble
in the urine than uric acid. The duration of rasburicase therapy can vary, with a majority
receiving 2 days of therapy, but success has been seen with a single dose. Uric acid levels should
be monitored regularly and used as a guide for dosing. Rasburicase works quickly with
decreases in the level of uric acid by 0.5–1 mg/dL being observed within 4 h of administration
[70]. Patients with larger tumor burden may need longer therapy (up to 7 days) or twice daily
treatment [70, 78]. Rasburicase is dosed at 0.2 mg/kg/day infused over 30 min with the first
dose at least 4 h prior to start of cytotoxic therapy and continued for up to 5 days. Dosing
beyond 5 days or administration of more than one course is not recommended [79]. The FDA‐
approved dose is 0.2 mg/kg dose, but 0.15 mg/kg has demonstrated efficacy, which may be an
option for intermediate‐risk patients with baseline uric acid ≤7.5 mg/dL [70]. Many institutions
are also utilizing fixed dosages (3, 6 or 7.5 mg) versus weight based dosing [97]. Once serum
uric acid levels normalize, rasburicase can be stopped and allopurinol treatment can be
initiated/resumed. Concomitant allopurinol should not be administered in order to avoid
xanthine accumulation and lack of substrate for rasburicase.
4.2. Pulmonary complications (non-infectious causes) following hematopoietic stem cell
transplantation (HCT)
Hematopoietic stem cell transplantation (HCT) is a treatment option for many malignant
hematological disorders. The conditioning chemotherapy regimens used are considered either
myeloablative where lethal doses of chemotherapy are given, with or without irradiation, or
non‐myeloablative where lower doses of chemotherapy are administered. Our lungs contain
an enormous capillary bed that is uniquely sensitive to the side effects of chemotherapy and
radiation therapy. Subsequently, a myeloablative conditioning regimen with lethal doses of
chemotherapy has a high likelihood of causing pulmonary complications. The estimated
incidence of pulmonary complications in HCT recipients ranges between 40 and 60% [80]. Such
complications can be further divided into infectious and non‐infectious causes. The non‐
infectious causes include pulmonary edema, engraftment syndrome (ES), diffuse alveolar
hemorrhage (DAH), idiopathic pneumonia syndrome (IPS), bronchiolitis obliterans organiz‐
ing pneumonia (BOOP), and pulmonary sarcoidosis. The risk of developing these complica‐
tions can occur at three different phases following a HCT. The neutropenic phase is described
as <30 days post‐HCT, the early phase includes 30–100 days post‐HCT, and the late phase is
known as >100 days post‐HCT. The following section will focus on a few of the non‐infectious
pulmonary complications that occur in the neutropenic phase (<30 days) post‐HCT.
Engraftment syndrome is equally common in autologous and allogenic HCT patients (7–11
and 10%, respectively). The median time to onset is 10 days post‐transplant and can manifest
up to 11 days. The syndrome is multifactorial consisting of the overproduction and release of
pro‐inflammatory cytokines and interaction between T cells, monocytes, and complement
activation during engraftment. A majority of the cases are mild and self‐limiting but the
moderate‐to‐severe cases require treatment with corticosteroids. Lack of response to cortico‐
steroid therapy leading to mechanical ventilation is a predictor of poor prognosis [76].
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Treatment for mild ES (transient low‐grade fevers with limited rash) includes discontinuing
G‐CSF and initiating empiric broad‐spectrum antibiotics. Moderate‐to‐severe ES with pulmo‐
nary involvement often requires treatment with corticosteroids such as methylprednisolone
doses ranging from 0.5 to 10 mg/kg/day or methylprednisolone 1–2 g/day × 3 days followed
by rapid taper over 2–3 weeks. A decrease in O2 requirement should be observed with
symptoms improving in 2–4 days [13, 81, 82].
Diffuse alveolar hemorrhage (DAH) is a progressive, non‐infectious pulmonary complication
following HCT often leading to mechanical ventilation for respiratory failure in a majority of
patients. It is thought to be due to a combination of mechanisms such as lung tissue injury
from the conditioning regimen or pulmonary infections, inflammation likely due to a combi‐
nation of bronchial inflammation, alveolitis, GCSF induced neutrophil influx into the lungs,
or cytokine release which contributes to alveolar capillary endothelial membrane damage.
DAH occurs equally in approximately 5% of allogeneic and autologous HCT recipients with
the most common cause of death being multi‐organ failure and sepsis [76, 83–85]. Standard
therapy includes high‐dose corticosteroids with methylprednisolone 500–1000 mg/day for 3–
4 days followed by 1 mg/kg for 3 days then taper over 2–4 weeks. Doses of 125–250 mg IV
every 6 h for the first 4–5 days followed by a taper over 2–4 weeks have been associated with
higher overall survival as well. One retrospective study of 14 patients also showed an overall
higher survival benefit with aminocaproic acid 1000 mg IV q6 h plus methylprednisolone 250
mg IV every 6 h followed by a taper. In addition, several case reports have shown a modest
resolution in bleeding with the combination of recombinant factor VIIa 90 mcg/kg and
methylprednisolone 500–2000 mg IV daily followed by gradual taper over 2–4 weeks [76, 84–
86].
4.3. Cytokine release syndrome (CRS) associated with chimeric antigen receptors (CARs)
Immunotherapy is redefining the standard of care in many malignancies. Recent advances
involve the engineering of a patient’s own immune cells to recognize and attack tumor cells.
T cells contain a monoclonal antibody fragment (scFv) specific for a tumor target with T‐cell
receptor activation. The T cells are then directed to target antigens that are expressed by
tumors. This initiates the patient’s own immune system to target the cancer. However, CAR T‐
cell treatments are not without risks, and many people experience an inflammatory process
called severe cytokine release syndrome (CRS) that requires hospitalization, with over 30%
requiring intensive care admission [87].
Cytokine release syndrome (CRS) is marked by dramatic elevation in cytokine levels produc‐
ing a systemic inflammatory response similar to that of septic shock. The onset has been noted
to occur within 1–14 days of CD‐19 CAR T‐cell infusion and resolves typically in 2–3 weeks.
With hypotension being the main criteria in the revised CRS grading system, it is important
to record baseline blood pressure prior to start of therapy that could induce CRS. Potentially
life‐threatening complications with CRS include cardiac dysfunction, adult respiratory distress
syndrome, neurologic toxicity, renal failure, hepatic failure, and disseminated intravascular
coagulation [85]. Diagnosis of CRS is made based on the presence of high levels of inflamma‐
Oncology Critical Care58
tory markers and cytokines, increased LFTs, and increased total bilirubin [88]. Appropriate
treatment is based on the CRS grading system explained in Table 12.
CRS-revised grading system Treatment Associated with revised grading system
Grade 1
Symptoms are not life threatening
and require symptomatic treatment only:
Fever and constitutional symptoms
(nausea, fatigue, headache, myalgias,
malaise)
• Assess for infection in all grades
• Vigilant supportive care including antipyretics and analgesics in all grades1
Grade 2
Symptoms require and respond to
moderate intervention Oxygen
requirement <40% or Hypotension
responsive to fluids or Vasopressor if
unresponsive to
fluids or Grade 2 organ toxicity
• Monitor cardiac function (s/s cardiac decomposition). Cardiac
decompensation can be sudden and severe, but usually reversible. The
pathophysiology of acute cardiac toxicity in the setting of CRS is not clear,
but resembles cardiomyopathy associated with sepsis and stress
cardiomyopathy. Monitor echocardiography frequently in patients who are
a concern for cardiac dysfunction (Grade 2–4)
• Monitor organ function closely
• Monitor/manage complications of TLS
IF, older age or extensive comorbidities:
• Based on clinical judgment, may be necessary to initiate
immunosuppressive therapy (refer to Grade 3/4 treatment)
Grade 3
Symptoms require and respond to
aggressive intervention
Oxygen requirement ≥40% or
Hypotension requiring high dose
or multiple vasopressors or
Grade 3 organ toxicity or grade 4
transaminitis
• Initiate tocilizumab:
For patients weighing <30 kg: 12 mg/kg IV x1 dose
For patients weighing >30 kg: 8 mg/kg IV × 1 dose (max dose 800 mg)
Grade 4
Life‐threatening symptoms
Requirement for ventilator
support or Grade 4 organ toxicity
(excluding transaminitis)
IF, lack of clinical improvement while waiting for tocilizumab response:
• Initiate corticosteroid therapy (taper within one week; can generally be
accomplished)
Methylprednisolone* 2mg/kg x 1 dose, followed by 2mg/kg/d divided 4
times per day [24] to hopefully suppress the inflammatory cascade and
prevent irreversible organ dysfunction
Grade 5—Death
*Emerging evidence suggests corticosteroids may mediate a greater adverse effect on the antitumor activity of
adoptively transferred T cells [26]
1 Vigilant supportive care: antipyretics, analgesics, adequate hydration, blood pressure support, and broad‐spectrum
antibiotics.
2 For patients with severe neurologic symptoms, consider dexamethasone (0.5 mg/kg; maximum 10 mg/dose) due to
more efficient penetration of the blood‐brain barrier although evidence for choosing one over the other has not been
established.
Table 12. Cytokine release syndrome–revised grading system and associated treatment [88–90].
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Tocilizumab is an antirheumatic disease modifying interleukin‐6 receptor antagonist approved
for adults with rheumatoid arthritis at the dose 4–8 mg/kg every 4 weeks infused over 1 h [88].
It is also the standard therapy for managing Grade 3 CRS. Reports have shown cytokines return
to normal and symptoms resolve concurrently by day nine following tocilizumab adminis‐
tration [87, 91]. In addition, tocilizumab may have less impact on the antitumor effect of CAR
t cells when compared to corticosteroids [88]. If the patient has a positive clinical response to
tocilizumab, then vasopressors and supportive measures can be weaned shortly thereafter. If
the patient’s condition does not improve or stabilize within 24 h of tocilizumab dose, a second
dose can be administered. A corticosteroid regimen should also be considered if it has not
already been initiated. Adverse effects (AE) associated with tocilizumab include, but are not
limited to: hypersensitivity reactions, elevated liver enzymes, fatal opportunistic infections,
gastrointestinal perforation, hematologic effects, herpes zoster reactivation, hyperlipidemia,
and tuberculosis. Studies are under investigation regarding the optimal timing of anti‐Il‐6
treatment, but some levels of CRS should be expected and possibly an inevitable consequence
of the CAR T‐cell therapy mechanism [92].
4.4. Pulmonary toxicity due to chemotherapy agents in general oncology patients
In the non‐HCT patients, several other chemotherapy agents have high risks for causing
pulmonary toxicity exhibited early with infiltrates, pulmonary edema, hypersensitivity
reactions, and pleural effusions or with infiltrates or fibrosis in late onset (greater than 2
months). These injuries can be dose dependent or can manifest several years after completion
of therapy [93]. As a result, the most severe and late stages of such toxicity are usually observed
in patients admitted to the ICU. The most common chemotherapy agents associated with
pulmonary toxicity and their respective clinical/radiologic manifestations are described in
Table 13. The mainstay treatment for such pulmonary complications are largely steroids;
however, it has yet to be determined the appropriate dose and duration of therapy that is most
effective. One study evaluated the dosage pattern of corticosteroids used in 398 lung cancer
patients with pulmonary toxicity. The drug‐induced interstitial lung diseases were primarily
treated with pulse dose therapy (≥500 mg/day methylprednisolone for 3 days followed by high‐
dose steroids) and high‐dose therapy (≥0.5 mg/kg/day prednisolone). These cases had a
mortality rate of 48.4% which was similar or less than that of the other groups. Unfortunately,
response to therapy was not defined in this study by improvements in radiologic findings or
carbon monoxide diffusing capacity, which has been suggested as better indicators [94]. Scarce
literature exists outside of case series or small observation studies as the one described.
Therefore, with the lack of established treatment guidelines for pulmonary toxicity, intensivists
should customize corticosteroid regimens based on each patient’s response and risk for AEs
from prolonged therapy.
Despite the many advances in cancer treatment options including not only chemotherapy but
also immunotherapy agents, the risks for AEs have unfortunately not been completely
diminished. These agents are administered at toxic levels with multiple cycles, and each dose
highly affects more than one organ system. Therefore, the risks observed from these agents far
outweigh AEs due to therapies initiated in typical ICU patients. The AEs previously discussed
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are only a few of the many acute and chronic consequences that are observed in cancer patients
leading to ICU admission. However, the pharmacologic management of such occurrences is
extremely important as they affect future treatment options and overall quality of life of the
patient.
Chemotherapy agent Clinical/radiological manifestations 
Bleomycin  Bronchiolitis obliterans organizing pneumonia (now referred to as cryptogenic organizing
pneumonia), eosinophilic hypersensitivity, or interstitial pneumonitis (most common) that can
progress to fibrosis 
Methotrexate  Bilateral interstitial and alveolar infiltrates or pleural effusions, accompanied by fever and
peripheral eosinophilia. Fibrosis can be prevented if the medication is discontinued 
Gemcitabine  Diffuse ground‐glass changes accompanied by thickened septal lines, interstitial infiltrates, or
diffuse alveolar infiltrates, which may lead to acute respiratory distress syndrome 
Paclitaxel  Bilateral reticular or ground‐glass infiltrates or focal consolidation 
Oxaliplatin  Interstitial pneumonitis with fibrosis occurring after 3–6 months of therapy. Patients can
present with slow progressive cough and dyspnea 
EGFR‐targeted
inhibitors: gefitinib
and erlotinib 
Airspace consolidation or extensive bilateral ground‐glass infiltrates 
Table 13. Common chemotherapy agents associated with pulmonary toxicity and clinical/radiological manifestations
[005B93].
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